Diligence memo · auto-generated · as of July 2, 2026

Proteus Biomedical Inc

Proteus Biomedical Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Proteus Biomedical Inc operates in Other Health Care, based in REDWOOD CITY.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Proteus Biomedical Inc has raised $162M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $119M on 2014-05-13.

Most recent recorded round closed around 2014-05-13.

Valuation (modeled)modeled

Provath models Proteus Biomedical Inc at approximately $2.7B (range $637M–$6.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.05× the median modeled value of Series D+ Other Health Care companies in 2013–2015 (16 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 26 months.

Last raise 12.1 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 6.8× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 98% of Other Health Care peers (5377 compared).

Modeled value ranks above 99% of those peers.

Closest niche peers: Onex TSG Holdings Corp., BVO Holdings, LLC, Mdp Hc Holdings, Llc, Amsurg Corp, Greatbatch, Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.